Literature DB >> 3997420

Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits.

C Tremblay, M Barza, F Szoka, M Lahav, J Baum.   

Abstract

The ocular toxicity of liposome-intercalated amphotericin B and commercial amphotericin B were compared after intravitreal injection in healthy pigmented rabbits. Ophthalmoscopic observations over 5 weeks following a single intravitreal injection showed vitreal band formation and focal retinal damage after doses of commercial amphotericin B as low as 5 micrograms. Such lesions were not seen in animals given liposomal amphotericin B in doses up to 20 micrograms. Histopathologic examination showed areas of retinal atrophy or necrosis in five of 16 rabbits given commercial amphotericin B in doses of 5-20 micrograms but in none of 16 rabbits given the same doses of liposomal amphotericin B (P = 0.02). Small white vitreal bodies were seen clinically in virtually all animals given liposomal amphotericin B or "empty" (drug-free) liposomes but in only a few animals given commercial amphotericin B; these deposits may represent residual lipid. Concentrations of amphotericin B ranged from 0.4 to 1.0 micrograms per ml of vitreous humor 5 weeks after injection of 5-20 micrograms of either formulation. These studies indicate that liposome association markedly reduces the ocular toxicity of amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3997420

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Liposome-bound cyclosporine: retinal toxicity after intravitreal injection.

Authors:  A A Alghadyan; G A Peyman; B Khoobehi; K R Liu
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

Review 2.  Liposomes as delivery systems in the prevention and treatment of infectious diseases.

Authors:  J J Bergers; T L ten Hagen; E W van Etten; I A Bakker-Woudenberg
Journal:  Pharm World Sci       Date:  1995-01-27

Review 3.  Pharmacology of bile acids and their derivatives: absorption promoters and therapeutic agents.

Authors:  M Mikov; J P Fawcett; K Kuhajda; S Kevresan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Jul-Sep       Impact factor: 2.441

4.  Intravitreal liposome-encapsulated drugs: a preliminary human report.

Authors:  G A Peyman; H C Charles; K R Liu; B Khoobehi; M Niesman
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

Review 5.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

6.  Corticosteroids and daunomycin in the prevention of experimental proliferative vitreoretinopathy induced by macrophages.

Authors:  Y N Hui; H C Liang; Y S Cai; B Kirchhof; K Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

7.  Liposome-encapsulated 3H-5FU in rabbits.

Authors:  P Fishman; G A Peyman; R Hendricks; S L Hui
Journal:  Int Ophthalmol       Date:  1989-09       Impact factor: 2.031

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

9.  Liposomes dispersed within a thermosensitive gel: a new dosage form for ocular delivery of oligonucleotides.

Authors:  A Bochot; E Fattal; A Gulik; G Couarraze; P Couvreur
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

10.  Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis.

Authors:  V S Rao; G A Peyman; B Khoobehi; S Vangipuram
Journal:  Int Ophthalmol       Date:  1989-05       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.